Department of Medical Sciences/Clinical Chemistry, Uppsala University, Uppsala, Sweden
Hedenstierna laboratory, CIRRUS, Department of Surgical Sciences/Anesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden.
Heart. 2022 Feb;108(4):279-284. doi: 10.1136/heartjnl-2020-318860. Epub 2021 Apr 1.
OBJECTIVE: Decreased kidney function increases cardiovascular risk and predicts poor survival. Estimated glomerular filtration rate (eGFR) by creatinine may theoretically be less accurate in the critically ill. This observational study compares long-term cardiovascular mortality risk by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation; Caucasian, Asian, paediatric and adult cohort (CAPA) cystatin C equation and the CKD-EPI combined creatinine/cystatin C equation. METHODS: The nationwide study includes 22 488 intensive care patients in Uppsala, Karolinska and Lund University Hospitals, Sweden, between 2004 and 2015. Creatinine and cystatin C were analysed with accredited methods at admission. Reclassification and model discrimination with C-statistics was used to compare creatinine and cystatin C for cardiovascular mortality prediction. RESULTS: During 5 years of follow-up, 2960 (13 %) of the patients died of cardiovascular causes. Reduced eGFR was significantly associated with cardiovascular death by all eGFR equations in Cox regression models. In each creatinine-based GFR category, 17%, 19% and 31% reclassified to a lower GFR category by cystatin C. These patients had significantly higher cardiovascular mortality risk, adjusted HR (95% CI), 1.55 (1.38 to 1.74), 1.76 (1.53 to 2.03) and 1.44 (1.11 to 1.86), respectively, compared with patients not reclassified. Harrell's C-statistic for cardiovascular death for cystatin C, alone or combined with creatinine, was 0.73, significantly higher than for creatinine (0.71), p<0.001. CONCLUSIONS: A single cystatin C at admission to the intensive care unit added significant predictive value to creatinine for long-term cardiovascular death risk assessment. Cystatin C, alone or in combination with creatinine, should be used for estimating GFR for long-term risk prediction in critically ill.
目的:肾功能下降会增加心血管风险并预测生存率降低。理论上,肌酐估计肾小球滤过率(eGFR)在危重病患者中可能不太准确。本观察性研究比较了慢性肾脏病流行病学协作组(CKD-EPI)肌酐方程、白种人、亚洲人、儿科和成人队列(CAPA)胱抑素 C 方程和 CKD-EPI 联合肌酐/胱抑素 C 方程预测长期心血管死亡率的风险。
方法:这项全国性研究纳入了 2004 年至 2015 年期间在瑞典乌普萨拉、卡罗林斯卡和隆德大学医院的 22488 例重症监护患者。入院时采用经认证的方法分析肌酐和胱抑素 C。使用 C 统计量进行重新分类和模型判别,以比较肌酐和胱抑素 C 对心血管死亡率的预测。
结果:在 5 年的随访期间,2960 例(13%)患者死于心血管原因。在 Cox 回归模型中,所有 eGFR 方程均显示,降低 eGFR 与心血管死亡显著相关。在每个基于肌酐的 GFR 类别中,17%、19%和 31%的患者通过胱抑素 C 重新分类到较低的 GFR 类别。与未重新分类的患者相比,这些患者的心血管死亡率风险显著更高,调整后的 HR(95%CI)分别为 1.55(1.38 至 1.74)、1.76(1.53 至 2.03)和 1.44(1.11 至 1.86),p<0.001。单独使用胱抑素 C 或与肌酐联合使用时,心血管死亡的 Harrell C 统计量为 0.73,明显高于肌酐(0.71),p<0.001。
结论:在重症监护病房入院时单次检测胱抑素 C 可显著提高肌酐对长期心血管死亡风险评估的预测价值。胱抑素 C 单独或与肌酐联合使用时,应用于估计危重病患者的 GFR 以进行长期风险预测。
Front Endocrinol (Lausanne). 2025-3-3
Eur J Heart Fail. 2025-1-17
J Am Coll Cardiol. 2016-8-30
Biomed Res Int. 2014
JAMA. 2013-10-16
N Engl J Med. 2013-9-5